Chemomab Therapeutics (CMMB) Cash from Financing Activities (2017 - 2023)

Chemomab Therapeutics (CMMB) has 7 years of Cash from Financing Activities data on file, last reported at $2.1 million in Q4 2023.

• For the quarter ending Q4 2023, Cash from Financing Activities rose 345.45% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2023 stood at $3.5 million (up 533.66% YoY), and the FY2025 full-year result was $7.2 million, down 27.47% from the prior year.
• Cash from Financing Activities for Q4 2023 stood at $2.1 million, up from $3000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $47.8 million in Q1 2021 and bottomed at -$1.2 million in Q2 2019.
• The 5-year median for Cash from Financing Activities is $531000.0 (2020), against an average of $5.9 million.
• The widest annual swing landed in 2021, when Cash from Financing Activities surged 9459.8%; it then plunged 972.84% in 2022.
• A 5-year view of Cash from Financing Activities shows it stood at -$1.2 million in 2019, then surged by 146.99% to $563000.0 in 2020, then plunged by 114.39% to -$81000.0 in 2021, then slumped by 972.84% to -$869000.0 in 2022, then jumped by 345.45% to $2.1 million in 2023.
• The last three Cash from Financing Activities figures came in at $2.1 million (Q4 2023), $3000.0 (Q3 2023), and $1.4 million (Q2 2023), per Business Quant data.

Peer Comparison